Lancashire (LRE) Competitors

Mediclinic International (LON:MDC) and Lancashire (LON:LRE) are both construction companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

Which has more volatility and risk, MDC or LRE?

Mediclinic International has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Lancashire has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.

Is MDC or LRE a better dividend stock?

Mediclinic International pays an annual dividend of GBX 3 per share. Lancashire pays an annual dividend of GBX 18 per share and has a dividend yield of 3.1%. Mediclinic International pays out 1,304.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Lancashire pays out 34.3% of its earnings in the form of a dividend. Lancashire is clearly the better dividend stock, given its higher yield and lower payout ratio.

Do institutionals & insiders believe in MDC or LRE?

39.2% of Mediclinic International shares are held by institutional investors. Comparatively, 60.5% of Lancashire shares are held by institutional investors. 48.9% of Mediclinic International shares are held by insiders. Comparatively, 0.6% of Lancashire shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Is MDC or LRE more profitable?

Lancashire has a net margin of 37.12% compared to Mediclinic International's net margin of 4.99%. Lancashire's return on equity of 10.76% beat Mediclinic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mediclinic International	4.99%	5.50%	2.30%
Lancashire	37.12%	10.76%	6.75%

Do analysts rate MDC or LRE?

Lancashire has a consensus target price of GBX 670, indicating a potential upside of 14.53%. Given Lancashire's stronger consensus rating and higher probable upside, analysts plainly believe Lancashire is more favorable than Mediclinic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mediclinic International	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lancashire	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has higher earnings and valuation, MDC or LRE?

Lancashire has lower revenue, but higher earnings than Mediclinic International. Mediclinic International is trading at a lower price-to-earnings ratio than Lancashire, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mediclinic International	£3.38B	0.00	£169M	£0.23	N/A
Lancashire	£536.12M	3.29	£199.02M	£52.49	11.14

Does the media favor MDC or LRE?

In the previous week, Mediclinic International's average media sentiment score of 0.00 equaled Lancashire'saverage media sentiment score.

Company	Overall Sentiment
Mediclinic International	Neutral
Lancashire	Neutral

Summary

Lancashire beats Mediclinic International on 11 of the 14 factors compared between the two stocks.